Clinical Trial Update: Study of GV20-0251 in Participants With Solid Tumor Malignancies [Phase 1, Phase 2]

View source ↗

Summary

GV20 Therapeutics is evaluating GV20-0251 in a Phase 1/2 trial for adults with various solid tumors, and the study is currently recruiting. Indications include …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Endometrial Carcinoma
• Head and Neck Squamous Cell Carcinoma
• Hepatocellular Carcinoma
• Melanoma
• Non-small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• GV20-0251

Snippet

Sponsor: GV20 Therapeutics | Conditions: Solid Tumor Cancer, Adult Refractory Cancer | Phase 1, Phase 2 | Status: RECRUITING